Roivant re­veals its newest 'vant,' try­ing to re­boot an Ei­sai blood can­cer pro­gram and out­flank Mer­ck, Bris­tol My­ers

Roivant Sci­ences wel­comed the newest ad­di­tion to its fam­i­ly of “vants” on Mon­day dur­ing its fourth quar­ter and full-year 2021 up­date.

The bio­phar­ma un­veiled Hema­vant as its lat­est sub­sidiary, pack­ag­ing the com­pa­ny launch with a com­pound in-li­censed from Ei­sai last month. Hema­vant will aim to re­pur­pose the mol­e­cule, for­mer­ly H3B-8800 and re­brand­ed as RVT-2001, to treat trans­fu­sion-de­pen­dent ane­mia in cer­tain pa­tients with low-risk myelodys­plas­tic syn­dromes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER